DexCom(US:DXCM) Prnewswire·2025-11-07 21:00Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud related to the company's glucose monitoring products, specifically the G6 and G7 models, which are claimed to have undergone unauthorized design changes that compromised their reliability and safety [1][2]. Group 1: Allegations and Impact - The lawsuit claims that DexCom made material design changes to the G6 and G7 glucose monitoring products without FDA authorization [2]. - These design changes allegedly rendered the devices less reliable, posing a material health risk to users who depend on them for accurate glucose readings [2]. - The enhancements claimed by the defendants regarding the G7's reliability, accuracy, and functionality were reportedly overstated [2]. - The lawsuit suggests that the company downplayed the severity of the issues and health risks associated with the altered G7 devices [2]. - As a result of these actions, DexCom is said to face increased regulatory scrutiny and potential legal, reputational, and financial harm [2]. - The public statements made by the defendants are characterized as materially false and misleading throughout the relevant time period [2]. Group 2: Legal Process and Participation - Investors who suffered losses in DexCom during the specified timeframe have until December 26, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require individuals to serve as lead plaintiffs, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant recoveries for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].